Literature DB >> 11391688

Incremental net benefit in randomized clinical trials.

A R Willan1, D Y Lin.   

Abstract

There are three approaches to health economic evaluation for comparing two therapies. These are (i) cost minimization, in which one assumes or observes no difference in effectiveness, (ii) incremental cost-effectiveness, and (iii) incremental net benefit. The latter can be expressed either in units of effectiveness or costs. When analysing data from a clinical trial, expressing incremental net benefit in units of cost allows the investigator to examine all three approaches in a single graph, complete with the corresponding statistical inferences. Furthermore, if costs and effectiveness are not censored, this can be achieved using common two-sample statistical procedures. The above will be illustrated using two examples, one with censoring and one without. Copyright 2001 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2001        PMID: 11391688     DOI: 10.1002/sim.789

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  25 in total

Review 1.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 2.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 3.  The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy.

Authors:  David B Rein; John S Wittenborn; Xinzhi Zhang; Benjamin A Allaire; Michael S Song; Ronald Klein; Jinan B Saaddine
Journal:  Health Serv Res       Date:  2011-04-14       Impact factor: 3.402

4.  Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

5.  Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial.

Authors: 
Journal:  BMJ       Date:  2002-11-16

6.  Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care.

Authors:  J M Joesch; C D Sherbourne; G Sullivan; M B Stein; M G Craske; P Roy-Byrne
Journal:  Psychol Med       Date:  2011-12-13       Impact factor: 7.723

7.  Incremental Net Benefit of Early Intervention for Preschool-Aged Children with Emotional and Behavioral Problems in Foster Care.

Authors:  Frances L Lynch; John F Dickerson; Lisa Saldana; Phillip A Fisher
Journal:  Child Youth Serv Rev       Date:  2013-12-05

8.  The potential cost-effectiveness of amblyopia screening programs.

Authors:  David B Rein; John S Wittenborn; Xinzhi Zhang; Michael Song; Jinan B Saaddine
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2011-08-30       Impact factor: 1.402

9.  Nonparametric inference for time-dependent incremental cost-effectiveness ratios.

Authors:  Laura M Yee; Kwun Chuen Gary Chan
Journal:  Stat Med       Date:  2015-07-27       Impact factor: 2.373

10.  Cost effectiveness analysis of laparoscopic hysterectomy compared with standard hysterectomy: results from a randomised trial.

Authors:  Mark Sculpher; Andrea Manca; Jason Abbott; Jayne Fountain; Su Mason; Ray Garry
Journal:  BMJ       Date:  2004-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.